NCT04867941View on ClinicalTrials.gov

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 21, 2014

Primary Completion Date

February 2, 2015

Study Completion Date

February 2, 2015

Conditions
Hepatic Insufficiency
Interventions
DRUG

ACP-196

All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.

Trial Locations (3)

32809

Research Site, Orlando

33136

Research Site, Miami

37920

Research Site, Knoxville

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY

NCT04867941 - A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196 | Biotech Hunter | Biotech Hunter